OR RE Model |
Standard Dose Model Median (95% CI) |
Unadjusted Model Median (95% CI) |
Dose Adjusted Model Median (95% CI) |
Abatacept | 0.97 (0.40 to 2.31) | 1.19 (0.62 to 2.27) | 1.08 (0.48 to 2.48) |
Adalimumab | 1.23 (0.65 to 2.40) | 1.26 (0.74 to 2.20) | 1.30 (0.73 to 2.42) |
Anakinra | 4.05 (1.22 to 16.84)* | 3.96 (1.27 to 15.75)* | 4.03 (1.29 to 16.22)* |
Certolizumab | 4.75 (1.52 to 18.45)* | 4.65 (1.61 to 16.22)* | 4.67 (1.58 to 16.15)* |
Etanercept | 1.29 (0.72 to 2.45) | 1.19 (0.72 to 2.01) | 1.28 (0.73 to 2.30) |
Golimumab | 1.11 (0.45 to 2.59) | 1.30 (0.65 to 2.65) | 1.14 (0.49 to 2.55) |
Infliximab | 1.41 (0.75 to 2.62) | 1.58 (1.08 to 2.36)* | 1.17 (0.65 to 2.09) |
Rituximab | 0.26 (0.03 to 2.16) | 1.17 (0.76 to 1.85) | 0.46 (0.16 to 1.15) |
Tocilizumab | 0.84 (0.20 to 3.56) | 1.52 (0.72 to 3.32) | 0.78 (0.22 to 2.60) |
Overall | 1.37 (1.04 to 1.82)* | ||
Data points Residual deviance DIC |
(115) 123.2 494.12 |
(163) 221.8 895.53 |
(208) 221.5 902.03 |